Which should a med spa use?
For compounded product your clinic keeps on hand and administers in-office, use a 503B outsourcing facility. 503B facilities are FDA-registered, compound under federal cGMP standards, and can supply office stock without a named patient on each unit.
For a compounded medication prescribed to one named patient, use a 503A pharmacy. A 503A pharmacy compounds against that prescription and ships to the patient or to your clinic for that patient.
Most med spas use both. The split is by use (office stock versus a patient-specific prescription), not by preference.
| What differs | 503A compounding pharmacy | 503B outsourcing facility |
|---|---|---|
| Primary oversight | State boards of pharmacy (state-by-state licensure) | FDA-registered; federal cGMP; FDA inspections |
| Prescription required? | Yes: one named patient, per prescription | No patient name required on each unit; supplied to a practice under a medication order |
| Office stock allowed? | Generally no: patient-specific fulfilment | Yes: standardized batches for in-clinic administration |
| Federal cGMP? | No: state board of pharmacy standards govern; federal insanitary-conditions rules still apply | Yes: federal cGMP, with FDA inspections |
| How your clinic uses it | Direct-to-patient fulfillment: the telehealth workhorse | Office stock administered in-clinic under a medication order |
| Beyond-use dating | Generally shorter, set per preparation | Generally longer, supporting practice-level inventory |
| Ordering paperwork | Patient-specific prescription each time | Practice-level medication orders / stock purchasing |
| Where it can ship | States where that pharmacy is licensed | Per its registrations and state rules |
What is a 503A compounding pharmacy?
"503A" refers to section 503A of the federal Food, Drug, and Cosmetic Act. These are what most people picture when they hear "compounding pharmacy": a pharmacist prepares a customized formulation (a specific strength, combination, or dosage form) because a prescriber decided it fits that individual patient.
503A pharmacies are regulated primarily by their state boards of pharmacy, and each pharmacy can only ship into states where it holds a license. When a 503A pharmacy meets the law's conditions, it is exempt from certain federal requirements that apply to drug manufacturers, which is exactly why the patient-specific prescription requirement matters so much: it's the legal foundation the whole model rests on.
For your clinic, the practical picture is: patient is seen (in person or via telehealth) → provider writes a patient-specific prescription → the 503A pharmacy compounds it and ships it to the patient or to your clinic for that patient.
What is a 503B outsourcing facility?
The 503B category is newer, created by federal law in 2013. Where a 503A pharmacy makes one preparation for one patient, a 503B facility operates more like a small, federally inspected manufacturer: it produces uniform batches under current Good Manufacturing Practice (cGMP) (the same quality framework conventional drug manufacturers follow) and is subject to FDA registration, inspections, and adverse-event reporting.
Because 503B products don't require a patient name per unit, a licensed practice can purchase them as office stock: medication kept on hand and administered in-clinic under a provider's medication order. 503B products also typically carry longer beyond-use dating than patient-specific 503A preparations, which makes inventory planning realistic.
Neither pathway produces FDA-approved products (more on that below), but the two categories exist precisely so that patient-specific customization and standardized office supply each have a lawful, regulated lane.
Can my practice use both?
The mistake we see most often isn't choosing the "wrong" type: it's building the whole practice on a single pharmacy relationship of either type. One pharmacy means one set of state licenses, one price list, one shipping operation, and zero leverage. When that pharmacy has a supply interruption or a licensing gap in a state you serve, your patients feel it. A network approach (multiple 503A and 503B options in one workflow) is how practices keep coverage and pricing honest.
If you're building a medication program from scratch (say, adding GLP-1 weight management) the pharmacy relationship is step two, after prescriber coverage. Order matters.
Are compounded medications FDA-approved?
This is the single most important compliance fact in this space, and it's worth internalizing because it shapes what a practice can honestly say in its own marketing. "Compounded" means prepared outside the FDA's drug-approval process. The regulation that does exist (state board oversight for 503A, federal cGMP and inspections for 503B) governs how the product is made, not whether the FDA has evaluated it the way an approved drug is evaluated. Practices should never describe a compounded product as FDA-approved, or as equivalent to an approved brand-name drug.
Where did these rules come from?
The 2012 New England Compounding Center tragedy is the reason this two-lane system exists. Congress responded by drawing a bright line: traditional patient-specific compounding stays primarily under state oversight (503A), while anyone producing standardized batches for office use must step up to federal registration, cGMP manufacturing standards, and FDA inspection (503B). Understanding that history explains why the paperwork differences aren't bureaucratic trivia: they're the safety architecture.
What should I verify before partnering with any compounding pharmacy?
- State licensure map. A pharmacy is only useful to you in states where it's licensed. Ask for the current list and compare it against where your patients actually are.
- FDA registration (503B). Any facility selling you office stock should appear on the FDA's public list of registered outsourcing facilities. Check it yourself; the link is in the sources below.
- Third-party certification. LegitScript certification is an independent signal that a pharmacy's operations and marketing have been vetted.
- Quality documentation. Ask what documentation accompanies products and what's available on request. A quality operation answers this quickly; a defensive answer tells you something too.
- Logistics and support. Cold-chain handling, shipping speed, reshipment policy, and whether a human answers when an order goes sideways: this is where patient experience is actually won or lost.
- Ongoing re-verification. Licenses lapse and registrations change. Ask who is responsible for monitoring that over the life of the relationship, because if the answer is "nobody," it's you.
This vetting is, candidly, the job Eventide does for its clinics across a network of pharmacies, so providers compare verified options instead of auditing them one at a time. If you'd rather not build this muscle in-house, that's what our pharmacy relationships page explains. The same documentation discipline applies to regenerative products too. See our exosome compliance guide and the supplies marketplace for how traceability works outside the pharmacy lane.
Office-use purchasing checklist
Before you engage any compounding partner for office stock, run these checks. This is not a substitute for legal or regulatory counsel, but it catches the gaps clinic operators most often miss.
- Confirm 503B registration on FDA's public list of registered outsourcing facilities before signing anything. Registration can lapse between your first check and your first shipment: re-check at each reorder.
- Request the most recent FDA inspection report or Form 483 history. FDA publishes inspection outcomes; our recommendation is to ask the facility for its own copy, and we treat reluctance to share it as a reason to keep looking.
- Verify the specific bulk drug substance is on the current 503B bulks list, or that the compounded drug is on FDA's shortage list at the time of compounding: this is the condition when a facility compounds from bulk, and it is not met just because the facility works in that therapeutic category.
- Review your medical director agreement to confirm it covers oversight for the compounds you plan to use. Our standing recommendation; what the agreement must cover varies by state.
- Confirm your state's office-use rules before relying on a 503A pathway for any compound. Do not rely on the pharmacy's reading of state law alone.
- Document everything with dates: registration confirmations, shortage-list status, and prescriber protocols, kept together per compound category.
In our experience the clinics that handle compounding compliance well are not the ones with the best vendor relationships: they are the ones with the best documentation habits.
GLP-1 and the enforcement picture
The short-supply window that gave clinics straightforward access to compounded GLP-1 receptor agonists is over. FDA declared the semaglutide injection shortage resolved in February 2025. For semaglutide, FDA set the end of its enforcement-discretion periods (the windows in which it did not intend to act against compounders working from the shortage listing) at April 22, 2025 for state-licensed 503A pharmacies and May 22, 2025 for 503B outsourcing facilities, or the date of the district court's decision on the pending injunction motion in the compounders' lawsuit, whichever came later. For tirzepatide the 503B window closed earlier, on March 19, 2025.
FDA has also proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list. The practical position today does not wait on that proposal: an outsourcing facility may compound from a bulk drug substance only if the substance is on the 503B bulks list or the compounded drug is on FDA's shortage list at the time of compounding, and per FDA, semaglutide and tirzepatide are currently on neither.
The two models bar copies differently. A 503A pharmacy may not compound, regularly or in inordinate amounts, a drug that is essentially a copy of a commercially available drug product, unless the prescriber documents a change that produces a significant difference for that patient. A 503B facility may not compound a drug that is essentially a copy of an approved drug. Both tests get materially harder to meet once the brand product is back in normal supply.
If your weight-management program depends on compounded GLP-1 medication, the model that worked during the shortage era may not be defensible today. Get the specific legal basis your pharmacy or facility is relying on in writing, from your own counsel: a supplier's confidence in its own posture is not a substitute for independent review. Our guide to adding GLP-1 weight management covers the program architecture.